JW LIFESCIENCE CORPORATION(KR:234080)
â‚©10,580.00+20.00 (+0.19%)
KR:234080
JW LIFESCIENCE CORPORATION financials statements
â‚©10,580.00
At close:+20.00 (+0.19%)
Want to see KR:234080 full AI Analyst Report?
JW LIFESCIENCE CORPORATION (234080) Ratios
JW LIFESCIENCE CORPORATION Ratios
KR:234080's free cash flow for Q2 2026 was ₩16.09B. For the 2026 fiscal year, KR:234080's free cash flow was decreased by ₩-1.34B and operating cash flow was ₩17.43B. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.05 | 1.32 | 1.14 | 1.31 | 0.77 |
| Quick Ratio | 0.67 | 0.88 | 0.90 | 1.04 | 0.52 |
| Cash Ratio | 0.10 | 0.09 | 0.21 | 0.05 | 0.06 |
| Solvency Ratio | 0.48 | 0.48 | 0.45 | 0.27 | 0.30 |
| Operating Cash Flow Ratio | 0.48 | 0.63 | 0.40 | 0.18 | 0.36 |
| Short-Term Operating Cash Flow Coverage | 0.83 | 1.42 | 0.82 | 0.38 | 0.68 |
| Net Current Asset Value | â‚© -9.34B | â‚© -19.21B | â‚© 11.39B | â‚© -7.60B | â‚© -23.54B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.16 | 0.21 | 0.18 | 0.27 | 0.21 |
| Debt-to-Equity Ratio | 0.23 | 0.35 | 0.29 | 0.48 | 0.35 |
| Debt-to-Capital Ratio | 0.19 | 0.26 | 0.23 | 0.32 | 0.26 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.14 | 0.00 | 0.18 | 0.01 |
| Financial Leverage Ratio | 1.44 | 1.62 | 1.61 | 1.80 | 1.67 |
| Debt Service Coverage Ratio | 0.93 | 1.63 | 0.93 | 0.95 | 0.70 |
| Interest Coverage Ratio | 11.74 | 17.40 | 11.46 | 8.76 | 22.18 |
| Debt to Market Cap | 0.25 | 0.40 | 0.23 | 0.36 | 0.21 |
| Interest Debt Per Share | 3457.63 | 4604.34 | 3164.74 | 4539.03 | 3066.05 |
| Net Debt to EBITDA | 0.82 | 0.80 | 0.51 | 1.45 | 1.11 |
| Profitability Margins | |||||
| Gross Profit Margin | 27.06% | 25.85% | 25.31% | 25.47% | 28.95% |
| EBIT Margin | 12.92% | 27.46% | 17.08% | 15.24% | 14.34% |
| EBITDA Margin | 19.94% | 34.53% | 24.57% | 23.14% | 22.12% |
| Operating Profit Margin | 12.92% | 16.12% | 14.92% | 14.34% | 16.73% |
| Pretax Profit Margin | 12.31% | 26.53% | 16.30% | 11.00% | 10.77% |
| Net Profit Margin | 11.09% | 19.77% | 13.61% | 7.92% | 7.60% |
| Continuous Operations Profit Margin | 11.09% | 19.77% | 13.61% | 7.92% | 7.60% |
| Net Income Per EBT | 90.11% | 74.52% | 83.49% | 71.99% | 70.62% |
| EBT Per EBIT | 95.32% | 164.61% | 109.22% | 76.72% | 64.35% |
| Return on Assets (ROA) | 8.99% | 13.52% | 11.00% | 5.91% | 5.88% |
| Return on Equity (ROE) | 12.97% | 21.94% | 17.66% | 10.66% | 9.82% |
| Return on Capital Employed (ROCE) | 14.25% | 14.63% | 19.10% | 15.67% | 20.96% |
| Return on Invested Capital (ROIC) | 10.60% | 9.50% | 12.41% | 9.28% | 11.12% |
| Return on Tangible Assets | 11.86% | 17.77% | 11.18% | 6.02% | 6.03% |
| Earnings Yield | 14.41% | 26.11% | 14.13% | 8.12% | 5.98% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.76 | 3.77 | 3.73 | 3.54 | 4.57 |
| Payables Turnover | 11.13 | 8.41 | 8.24 | 9.31 | 9.66 |
| Inventory Turnover | 5.95 | 4.65 | 6.60 | 6.38 | 5.72 |
| Fixed Asset Turnover | 2.00 | 1.68 | 1.66 | 1.44 | 1.24 |
| Asset Turnover | 0.81 | 0.68 | 0.81 | 0.75 | 0.77 |
| Working Capital Turnover Ratio | 17.57 | 11.39 | 10.74 | 68.79 | -10.53 |
| Cash Conversion Cycle | 91.99 | 131.92 | 108.94 | 121.19 | 105.91 |
| Days of Sales Outstanding | 63.41 | 96.89 | 97.94 | 103.18 | 79.95 |
| Days of Inventory Outstanding | 61.38 | 78.43 | 55.28 | 57.20 | 63.76 |
| Days of Payables Outstanding | 32.80 | 43.40 | 44.27 | 39.19 | 37.80 |
| Operating Cycle | 124.79 | 175.32 | 153.21 | 160.38 | 143.71 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 2624.25 | 3273.48 | 2426.49 | 912.42 | 1936.14 |
| Free Cash Flow Per Share | 1811.53 | 2607.89 | 1892.63 | 376.83 | 691.20 |
| Dividend Paid and CapEx Coverage Ratio | 2.00 | 2.81 | 2.35 | 0.88 | 1.10 |
| Capital Expenditure Coverage Ratio | 3.23 | 4.92 | 4.55 | 1.70 | 1.56 |
| Operating Cash Flow Coverage Ratio | 0.80 | 0.73 | 0.81 | 0.21 | 0.65 |
| Operating Cash Flow to Sales Ratio | 0.16 | 0.23 | 0.18 | 0.07 | 0.18 |
| Free Cash Flow Yield | 14.10% | 23.97% | 14.72% | 3.17% | 4.99% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 6.96 | 3.83 | 7.08 | 12.32 | 16.71 |
| Price-to-Sales (P/S) Ratio | 0.77 | 0.76 | 0.96 | 0.98 | 1.27 |
| Price-to-Book (P/B) Ratio | 0.90 | 0.84 | 1.25 | 1.31 | 1.64 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 7.09 | 4.17 | 6.79 | 31.58 | 20.04 |
| Price-to-Operating Cash Flow Ratio | 4.90 | 3.32 | 5.30 | 13.04 | 7.15 |
| Price-to-Earnings Growth (PEG) Ratio | -0.20 | 0.07 | 0.08 | 0.74 | -0.69 |
| Enterprise Value Multiple | 4.68 | 3.00 | 4.43 | 5.66 | 6.85 |
| Enterprise Value | 240.69B | 230.20B | 225.23B | 247.55B | 257.35B |
| EV to EBITDA | 4.68 | 3.00 | 4.43 | 5.66 | 6.85 |
| EV to Sales | 0.93 | 1.03 | 1.09 | 1.31 | 1.52 |
| EV to Free Cash Flow | 8.60 | 5.70 | 7.69 | 42.42 | 23.90 |
| EV to Operating Cash Flow | 5.94 | 4.54 | 5.99 | 17.52 | 8.53 |
| Tangible Book Value Per Share | 9290.26 | 7924.43 | 10026.95 | 8769.56 | 8098.88 |
| Shareholders’ Equity Per Share | 14279.67 | 12944.45 | 10293.39 | 9062.48 | 8439.80 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.10 | 0.25 | 0.17 | 0.28 | 0.29 |
| Revenue Per Share | 16691.23 | 14367.33 | 13358.76 | 12200.91 | 10899.68 |
| Net Income Per Share | 1851.87 | 2840.65 | 1817.50 | 966.18 | 828.86 |
| Tax Burden | 0.90 | 0.75 | 0.83 | 0.72 | 0.71 |
| Interest Burden | 0.95 | 0.97 | 0.95 | 0.72 | 0.75 |
| Research & Development to Revenue | 0.02 | 0.02 | 0.02 | 0.03 | 0.04 |
| SG&A to Revenue | 0.07 | 0.05 | 0.07 | 0.05 | 0.05 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.42 | 1.15 | 1.34 | 0.94 | 2.34 |
Currency in KRW

